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Breast cancer is one of the most pervasive malignancies in women in the world. Metastasis, the spread 
of malignant cells from a primary tumor to distant organs, is the main cause of death by cancer. The 
immune system interacts with cancer through its whole development processes, with its members, 
according to their phenotypes, involved in either suppression or support of malignant cells. Dendritic 
cells are significant in this response because of their roles as professional antigen-presenting cells. Their 
role is to initiate immune responses against cancer through the activation of the adaptive immune 
system. However, much less research has been done on the role of dendritic cells in metastasis, 
especially in early metastatic colonization. Dendritic cells secrete extracellular vesicles, particles carrying 
multiple molecules like proteins, microRNAs, lipids and metabolites inside or on their phospholipid 
bilayers, during antigen presentation and in development of cancer. However, currently we do not know 
the role of extracellular vesicles secreted by dendritic cells in response to metastasis. Here, we tried to 
investigate the involvement of lung dendritic cells during early stages of metastatic seeding of lungs. We 
injected tdTomato+ mammary tumor cells into wildtype mice and dissect lungs from them after certain 
time points. We then analyzed sections of lungs stained with an antibody against CD11c, the classical 
marker of dendritic cells. We found CD11c+ particles in metastases. We then testified whether those 
particles were really released by dendritic cells by staining them with CD24, a marker used to distinguish 
between dendritic cells and CD11c+ macrophages, showing that those particles were not released by 
dendritic cells. Besides characterizing particles, we also attempted to quantify dendritic cells 
surrounding metastases at different time points and comparing labeling of dendritic cells with CD11c 
only or with both CD11c and CD24. We cannot draw a definite conclusion about whether lung dendritic 
cells are involved in immune responses against infiltrating metastatic cells and more research is required 
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Breast cancer is one of the most common malignancies in women. At least one in ten women may suffer 
from breast cancer [1]. Although its mortality rate has decreased by about 40% in the United States in 
the past 30 years, breast cancer is still the second most common cause of death by cancer for women in 
this country [2].  
Breast cancer is commonly classified into five intrinsic molecular subtypes: luminal A, luminal B, HER2-
enriched, basal, and normal-like [3]. They are identified according to three classical 
immunohistochemistry markers, ER, PR and HER2, and proliferation is measured by Ki67 [4]. Luminal A 
and normal-like are marked by ER+PR+HER2-Ki67-; luminal B can be divided into two types: 
ER+PR+HER2-Ki67+ and ER+PR+HER2+Ki67+; HER2-enriched is identified as ER-PR-HER2+Ki67+; Basal is 
labeled as ER-PR-HER2-, and thus called triple-negative [5]. There is great diversity in prevalence and 
prognosis between five molecular subtypes: Luminal B and A are most common; prognosis of HER2-
enriched, basal and ER+PR+ HER2+Ki67+ Luminal B subtypes is worse than other subtypes [6]. Different 
gene expression profiles of the five subtypes determine different therapies for optimal treatment [4].  
Metastasis 
Metastasis is the spread of malignant cells from a primary tumor to one or more distant sites. It is the 
last stage of cancer and the main cause of death. While early stage breast cancer can be relevantly 
easier cured by local therapies such as surgery, metastatic breast cancer is still considered incurable. 
However, many therapies, including chemotherapies and immunotherapies, are being developed to 
treat metastasis [4], [7]. While the 5-year survival rate of early stage breast cancer was as high as about 
90%, this figure fell to less than 30% for metastatic stages, according to data between 2009 and 2015 [8].  
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Metastasis can be divided into five stages: invasion, intravasation, circulation, extravasation, and 
secondary-site colonization. Invasion is dissociation of individual cells or groups of cells from a primary 
tumor to surrounding tissue [9]; intravasation is dissociated cells entrance into blood or lymph vessels 
through the endothelium of the two types of vessels [10]; circulation is that of malignant cells through 
the circulatory system [11]; extravasation is circulating cells’ exit from blood vessels via the endothelium 
to enter secondary sites [12]; secondary-site colonization is the formation of metastatic tumors by 
seeded cells in distant sites [13][14]. It is widely believed that metastasis occurs through those five steps 
in a timely manner, although there are some disagreements stating that metastasis is independent of 
local invasion [15]. Although those stages involve different cell activities, some common properties 
shown by metastatic cells during the whole processes of metastasis have been summarized, from which 
heated debates also arise in academia. Some examples of those common properties are shown below.  
Metastasis has been believed to be carried out by individual cells, such as individual dissemination from 
primary tumors and colonization and growth of metastases by and from individual circulating malignant 
cells [16]. However, this observation has been challenged by multiple clinical and experimental 
observations that clusters formed by more than one malignant cell disseminate from primary tumors 
[17], circulate in blood vessels [18], and colonize secondary organs [19]. Cheung et al. showed that in 
PyMT-MMTV mice, a mouse cell line commonly used for breast cancer research, more than 95% 
metastases in lungs were developed from clusters rather than individual cells. He also showed that 
clusters were much more advantageous in colony formation in vitro, compared to individual cells [19].  
Most cancers, including breast cancer [20], show intratumoral heterogeneity (reviewed in [21]), which 
means that they are composed of multiple subpopulations with different phenotypes. Different 
subpopulations are diverse in their abilities, including those to invade and to resist therapies [21]. 
Certain subpopulations have been found to be more invasive and take dominant roles in metastasis. In 
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tumors in multiple breast cancer mouse models, a subpopulation expressing keratin-14 (K14), an 
intermediate filament protein and a marker for the basal state, although comprising a small proportion 
in primary tumors, were found to lead cancer invasion and dominate circulating tumor clusters and 
micrometastases just after colonization. However, its proportion declined to the primary tumor level as 
metastases grew [17], [19].  
Tumor cells have strong plasticity and are believed to experience phenotypic changes before and during 
metastasis so that they can be successfully seed in secondary organs [22]. Epithelial-mesenchymal 
transition (EMT) is a widely believed model about such phenotypical changes considered necessary for 
metastasis: in carcinomas, or cancers starting from epithelial tissues, malignant cells have to suppress 
expression of genes denoting epithelial phenotypes and promote expression of those denoting 
mesenchymal traits to increase their invisibility by decreasing cell-cell junctions and strengthening 
mechanical interactions between cells and extracellular matrices (ECM), and after successfully colonizing 
secondary organs, metastatic cells have to reverse to epithelial phenotypes again, i.e., mesenchymal-
epithelial transition (MET) (reviewed multiple times, such as in [23], [24]). However, the necessity of 
EMT in metastasis is challenged in multiple cancer types such as breast cancer [25], [26]. Some research 
shows that EMT is dispensable for metastasis but promotes resistance against chemotherapy of breast 
cancer lung metastasis [26]. Some research shows that EMT is even detrimental to metastasis because it 
leads to vulnerability to apoptosis induced by reactive oxygen species (ROS) [27]. The concept of EMT 
also keeps evolving, changing from a switch-like transition between epithelial and mesenchymal states 
to plasticity in a continuum between the two states, including multiple intermediate states (or “partial-
EMT” states), in which epithelial markers may not be downregulated when mesenchymal ones are 
upregulated [28]. In conclusion, the detailed mechanism of involvement of cancer cell plasticity in 
metastasis is still disputed.  
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Our research focuses on colonization, which, as mentioned above, is the last stage of metastasis. In this 
stage, metastatic tumor cells leaving the circulation system through extravasation are seeded in distant 
sites from primary tumors. After leaving blood vessels, malignant cells still need to go through multiple 
steps such as infiltration into secondary organs, evasion from the local immune system and other host 
defense mechanisms, settlement in supportive niches for survival, entry into dormancy, and outburst 
[13]. Compared with the microenvironment of a primary tumor, which is familiar to malignant cells and 
has been modified continuously to be increasingly tolerant to tumor growth and metastasis, the local 
microenvironment of a secondary organ can be much more unfriendly: different mechanical properties 
in extracellular matrices, different soluble factors and a relevantly intact local immune system [13], [29]. 
Such barriers lead to metastatic inefficiency, making organ colonization the most rate-limiting process of 
metastasis [13]: past research showed that more than half of tumor cells injected intravenously and 
metastasizing into lungs of immunodeficient mice were apoptotic 48 hours after tail vein injection [30]. 
Survival and proliferation pathways in metastatic cells can be inactivated spontaneously, can be 
suppressed by insufficient nutrients, or can be suppressed by immune cells, leading to dormancy that 
can last for years [31]. In such an adverse microenvironment, tumor cells that can sustain survival 
pathways relevant in the context of low levels of activating signals can persist [13]. It was found that 
primary tumors could release soluble factors and extracellular vesicles to secondary organs before 
arrival of metastatic cells, modifying local microenvironment, leading to formations of “pre-metastatic 
niches”, which were more favorable for survival and growth of metastatic cells [32].   
Involvement of the Immune System in Cancer 
Cancer cells constantly interact with their surrounding microenvironment, including ECM and non-
cancer cells, during cancer development and metastasis [33]. Different cell types of the immune system 
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are recruited to cancer and interact with cancer cells during different stages of cancer development and 
metastasis [34], [35].  
The immune system can distinguish cancer cells from normal cells by surface markers denoting cellular 
stress or abnormally upregulated in malignant cells. For example, phagocytic cells such as M1 
macrophages can sense phosphatidylserines and calreticulin, two “eat-me” signals to induce 
phagocytosis, which were found to be upregulated in cancer cells compared to normal cells [36], [37]. 
Natural killer cells (NK cells), first identified as professional anti-cancer cells without deliberate 
activation [38], can recognize stress molecules absent in normal cells but highly expressed in multiple 
types of cancer, such as Hsp70, B7-H6 and MIC A/B,  with NK activation receptors like NKp30 and NKG2D  
[39]-[41]. Neoantigens, which are mutated proteins presented by MHC I molecules, can induce 
cytotoxicity of CD8+ T cells, members of adaptive immunity [42]. Those cytotoxic T cells can also be 
stimulated by MHC-I-presented oncofetal and cancer-testis antigens, proteins that are normally 
expressed in fetuses or germ cells only [43], [44]. Furthermore, besides direct cytotoxicity, release of 
soluble factors by those cytotoxic cells themselves and other immune cell types such as CD4+ T cells and 
dendritic cells can strengthen cancer immunosurveillance by recruiting and activating more immune 
cells against transformed cells. 
However, during cancer development, strategies of malignant cells to evade immunosurveillance are 
developed [45], [46]. Cancer cells expressing fewer antigens are gradually selected under immune stress 
[47]. Activation of specific oncogenes such as β-catenin and c-Myc and loss of specific tumor suppressors 
such as PTEN can inhibit activation or recruitment of innate immune cells such as macrophages and 
dendritic cells that can recruit and activate T cells [45]. Some immunosuppressive molecules are 
expressed by transformed cells to prevent immune infiltration, such as PGE2, which can inhibit 
infiltration of NK cells and recruitment of dendritic cells [48]. Tumor cells can also inhibit cytotoxic 
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immune cells by hijacking mechanisms relevant to self-tolerance and wound healing. For example, 
tumor cells can express ligands that can bind to immune checkpoints such as PD-1 and CTLA-4 on T cells 
to inhibit their activities [49], [50].  
Tumor cells can also recruit or induce differentiation or conversion into “pro-tumor” immune cells that 
can inhibit anti-tumor ones and support cancer development and metastasis. For example, some types 
of cancer express IDO, which can both suppress cytotoxic immune cells such as CD8+ T cells and NK cells 
and generate immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived 
suppressive cells (MDSCs) [51]-[53]. Secretion of chemokines and cytokines such as CCL2 by tumor cells 
leads to polarization of macrophages towards tumor-associated phenotypes [54]. Those pro-tumor 
immune cells can inhibit anti-tumor immune cells. Besides, tumor-associated macrophages (TAMs) can 
even promote tumor development, releasing factors supporting growth, angiogenesis, metastasis, and 
therapy resistance [55]. 
Involvement of the Immune System in Metastasis 
Immune cells are also involved in metastasis [56]. Just like the case in primary tumors, CD8+ T cells and 
NK cells in secondary organs are mainly involved in immune surveillance against metastatic cells [57]. 
Interaction between local immune cells and metastatic cells cannot be decoupled from the primary 
tumor. On the one hand, immune response against a primary tumor is not limited locally but can induce 
concomitant immunity, which is anti-cancer immune response of the whole body, so that the possibility 
of secondary tumor occurrence is reduced [58]. On the other hand, factors released by primary tumors 
can polarize macrophages in secondary organs into pro-tumor phenotypes to help establish pre-tumor 
niches there [59]. Multiple pro-tumor immune cells such as neutrophils and MDSCs are shown to 




Dendritic cells (DCs) are significant players in the immune system because they function as a bridge 
connecting the innate and adaptive immune system by antigen presentation [62], [63]. After derivation 
from hematopoietic bone marrow progenitor cells, immature DCs are distributed to peripheral tissues 
such as skin, gut, and lungs. There they sample local microenvironment by macropinocytosis of 
extracellular fluid [62]. They also phagocytose small pieces of membranes from live cells for sampling 
[64]. Those immature cells can also directly phagocytose pathogens like bacteria they encounter. As long 
as pathogens are detected by their pattern recognition receptors, they start maturation, downregulating 
molecules relevant to pathogen sampling and recognition [65], expressing molecules relevant to 
chemotaxis such as CCR7, antigen presentation such as MHC I and II, and T cell activation such as CD80, 
CD86 and CD40 [66]. DCs start their migration to lymph nodes via lymph vessels or the spleen via blood 
vessels [67], [68]. During migration, DCs digest engulfed molecules into peptides that can be presented 
with MHC I and II molecules recognizable for T cells, i.e., antigens. DCs also experience morphological 
changes, including formation of dendrites during this process, becoming really “dendritic”. After arrival 
to the spleen or lymph nodes, DCs can activate T cells recognizing presented antigens by binding 
between antigens on MHC molecules on DCs and TCRs on T cells, stimulated by ligand-receptor binding 
of costimulatory molecules like CD40, CD80 and CD86, and release of cytokines. DCs can activate CD4+ 
helper T cells through presentation via MHC II and CD8+ cytotoxic T cells through MHC I, in which the 
latter is called cross-presentation. In this way, adoptive immunity can be activated against presented 
antigens [62], [69]. 
DCs are heterogeneous according to lineage and resident tissues in both human and mice (reviewed in 
[70], [71]). Besides those derived directly from bone marrow progenitor cells, DCs can also be 
differentiated from monocytes under induction [72]. Generally, DCs are classified into conventional DCs 
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(cDCs) and plasmacytoid DCs (pDCs), and cDCs can be further divided into cDC1s and cDC2s. cDC1s are 
specialized in cross-presentation of antigens to cytotoxic CD8+ T cells, although they can also present 
antigens to CD4+ T cells [73]. cDC2s are more specialized in presentation to CD4+ T cells [74]. pDCs 
release IFN-γ, an interferon that is involved in activation of multiple immune cell types upon viral 
infection [75].  
Dendritic Cells in Cancer 
As antigen-presenting cells that can initiate adoptive immunity against presented antigens, DCs take an 
important role in anti-cancer immunity [76]. In Chen and Mellman’s review [77], capture and 
presentation of neoantigens from malignant cells by DCs are considered as the first two steps in the 
cancer-immunity cycle, a cascade of immune responses after recognition of transformed cells, followed 
by infiltration of T cells in tumors. This model is further supplemented by observations in multiple solid 
tumors that DCs are recruited to tumors by NK cells that have infiltrated there [48], [78]. 
Among different subtypes of DCs, cDC1s are the most studied in their anti-cancer roles because of their 
abilities to directly activate cytotoxic CD8+ T cells by cross-presentation [48], [76]. However, other 
subtypes of DCs are also involved in cancer immunosurveillance directly or indirectly [79]. Injection of 
pDCs activated with tumor antigen-associated peptides into metastatic melanoma patients was found to 
induce anti-tumor T cell responses [80]. cDC2 can recruit CD4+ helper T cells, which have been shown to 
be required to maintain optimal cytotoxicity and prevent exhaustion of CD8+ T cells [81], [82]. Therefore, 
multiple subtypes of dendritic cells should be considered to explain DCs’ involvement in cancer immune 
surveillance. 
Tumors can prevent infiltration of immune cells by suppress activities of DCs. For example, 
downregulation of CCL4 induced by Wnt/β-catenin signaling was found to suppress infiltration of DCs 
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[83]. PGE2 was reported to suppress recruitment and activities of cDC1 to prevent infiltration of T cells 
[48]. DCs can be induced to be dysfunctional and immunosuppressive by malignant cells [84]. In an 
ovarian mouse model, DCs infiltrating in tumors were found to be transformed from immunostimulatory 
to immunosuppressive during cancer development because of PGE2 and TGF-β1 in tumor 
microenvironment (TME) [85]. Dysfunctional pDCs were reported to recruit Tregs and MDSCs to tumors 
and inhibit activities of cytotoxic T cells, and depletion of pDCs was found to reduce breast cancer bone 
metastases [86]. 
Compared with that on primary tumors, there is much less research on involvement of DCs in secondary 
organs seeded by metastases. In one paper covering this topic, DCs of an immunosuppressive subtype 
differentiated from monocytes were found to accumulate surround early pancreatic cancer liver 
metastases, which could recruit Tregs and inhibit CD8+ T cells [87]. Therefore, it requires further 
investigation whether DCs localized in secondary organs are involved in interaction with metastatic cells, 
especially anti-metastasis responses.  
 Identification of Dendritic Cells 
Identification and discrimination of different immune cell types and subtypes is challenging in peripheral 
tissues, such as tumors. Dendritic cells are heterogeneous and no exception. CD11c (Integrin alpha X) is 
a widely used dendritic cell marker in experiments with mice [88][89]. Some research uses CD11c as a 
definitive DC marker [90]. However, though once thought to be exclusive to DCs [91], CD11c can be 
expressed in other immune cells, such as macrophages [92]-[94]. Although in most of those cell types, 
CD11c is expressed at low level or transiently, macrophages resident in several organs, such as lungs and 
intestines, were found to express a similar level of CD11c to DCs during steady-state condition, 
according to flow cytometry [95]. Therefore, another marker is necessary for classification of dendritic 
cells and macrophages in mouse lungs. CD24, which is expressed in dendritic cells but not in 
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macrophages, has been used in this situation to distinguish the two myeloid cells in flow cytometry of 
several experiments [95]-[97]. In conclusion, additional staining of CD24 may improve the accuracy of 
DC labeling in immunofluorescence as in flow cytometry.  
Extracellular Vesicles 
Extracellular vesicles (EVs) are lipid-bilayer particles released by multiple types of cells. Containing 
various proteins, micro-RNAs, lipids, and other molecules, EVs can be used for cell-cell distant 
communication besides direct release of soluble factors or removal of waste from cells (reviewed in 
[98]). Generally, EVs released from normal cells are classified into exosomes and microvesicles (MVs, or 
ectosomes) according to size and mechanisms of genesis. Exosomes originate from endosomes formed 
by inward budding of the cellular membrane. These endosomes become multivesicular bodies (MVB) by 
accumulation of many smaller vesicles inside by further inward budding. Those smaller vesicles, 
containing cellular contents, are released from cells by fusion of MVBs with the cellular membrane, 
becoming exosomes [99].  MVs are directly released by outward blebbing of the cellular membrane, 
resulting from changes of lipid and protein components and Ca2+ levels [100]. The two MVs are mainly 
distinguished by their sizes: while the diameter of an exosome range from 30 to 150 nm, that of an MV 
range from 100 to 1000 nm [100]. They can also be labeled by their specific surface markers, such as 
CD9, CD63, and CD81 for exosomes and integrins and ARF6 for MVs [101], [102]. Besides, during 
apoptosis, dying cells release apoptotic bodies, 50-5000nm in size, containing anything in those cells, 
including fragments of nuclei [103]. As carriers of information between cells, EVs are involved in various 
physiological and pathological activities, including immune responses. 
11 
 
Extracellular Vesicles in Cancer 
Multiple types of EVs have been reported to be released by cells in tumor, both malignant and non-
malignant ones. Those EVs take important roles in immunity against cancer, cancer development, and 
metastasis [104], [105].  
During the whole process of cancer development, cancer cells release both exosomes and MVs, the 
latter of which are also called oncosomes and can be as large as 10 μm in diameter [106]. Those EVs can 
be absorbed by other malignant cells, so that oncogenic molecules can be shared by different tumor 
subpopulations [107]. EVs from tumor cells are also released to non-tumor cells in TME. Tumor EVs 
transferred to fibroblasts and endothelial cells were reported to facilitate metastasis by promoting ECM 
remodeling and angiogenesis [108], [109]. Those particles released by malignant cells are also received 
by immune cells, leading to mixed responses of the immune system. EVs containing MHC I and tumor 
antigens can induce immune responses by DCs and T cells against cancer [110], [111]. However, those 
tumor-cell-released EVs can promote immune evasion through modulation of immune cells by contents  
such as microRNAs and cytokines inside particles, including induction of apoptosis by immune cells, 
suppression of cytotoxic activities, recruitment of immunosuppressive immune cells, and induction of 
immunosuppressive phenotypes [112]-[115]. Tumor EVs can also enhance tumor-supporting activities of 
pro-tumor immune cells, such as angiogenesis [112]. During metastasis, EVs released from primary 
tumors can promote formation of pre-metastatic niches by increasing vascular leakiness, inducing 
angiogenesis, and recruiting pro-tumor cells or converting local-tissue resident cells [116]-[119].  
Non-tumor cells in TME also transfer EVs to surrounding tumor cells or non-tumor cells. Exosomes 
transferred from fibroblasts to cancer cells can promote tumor invasion and therapy resistance [120]. 
EVs secreted by immune cells can have a mixed influence on cancer development. On the one hand, 
macrophages can transfer exosomes with cancer antigens to dendritic cells [121]; dendritic cells can 
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implement antigen presentation via EVs to activate CD4+ and CD8+ T cells [122]; both can initiate anti-
cancer immune responses. On the other hand, EVs released by immunosuppressive cells such as Tregs 
can be transferred to anti-tumor immune cells to inhibit their activities [123]. Furthermore, EVs released 
by MDSCs were reported to promote breast cancer lung metastasis by inducing Th2 cells and 
angiogenesis [124]. However, direct transfer of EVs or even cytoplasmic contents from immune cells to 
cancer cells has been much more rarely reported, although it was reported that cytoplasmic contents of 
macrophages were directly transferred to melanoma via cell-cell contact, which enhanced dissemination 
of recipient malignant cells [125]. Therefore, investigation of transfer of EVs from immune cells to 
cancer cells is valuable. 
Dendritic Cells and Extracellular Vesicles 
DCs are one of the first cell types to be reported to secrete exosomes [122]. EVs with different sizes and 
markers have been found to be secreted by DCs. [102] Contents of EVs and relative proportions of 
exosomes and MVs are also different between immature and mature DCs [102], [126]. The EVs 
containing MHC I, MHC II or both can perform antigen presentation to T cells in place of or along with 
DCs in multiple ways: those EVs can be released by DCs in peripheral tissue and migrate to lymph nodes 
to activate T cells directly or indirectly after being recruited by bystander DCs in lymph nodes; they may 
also be still attached to DCs after secretion and presented to T cells after migration with associated DCs; 
DCs may form MVBs after being activated by pathogens and release vesicles inside MVBs as exosomes 
during antigen-presentation to T cells [127]. Besides MHC molecules, cytokines like IL-1β were also 
found to be contained in DC-released EVs [128]. However, exosomes derived from DCs treated with IL-
10 or TGF-β1 were reported to have immune suppression functions [129], [130].  
When they were first discovered in tumor-bearing mice, exosomes derived from DCs were already found 
to activate anti-cancer cytotoxic CD8+ T cells, and they could be used to eradicate tumors as vaccines 
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[122]. Those DC-derived exosomes can also activate NK cells with ligands to bind to multiple NK 
activation receptors such as TNFR, NKG2D, IL-15Ra, and NKp30 [131]-[133]. However, considering that 
TGF-β1 has been reported to induce phenotypical changes of DCs infiltrating to ovarian cancer, it is 
reasonable to deduce that their EVs are also immunosuppressive [85], [129]. 
About This Experiment  
In the experiment, we sought to investigate the interaction between CD11c+CD24+ dendritic cells 
resident in lungs and metastatic breast cancer cells during colonization of metastases in lungs. We 
injected mammary tumor clusters isolated from PyMT-MMTV mouse models into wildtype FVB mice 
through their tail veins. The PyMT-MMTV model is established through insertion of the gene of 
polyomavirus middle T antigen fused (PyMT) following long terminal repeats of the mouse mammary 
tumor virus (MMTV). The transgenically expressed PyMT oncogene transforms mammary epithelial cells 
because of activation of tyrosine kinase activities of c-Src families, leading to formation of tumors similar 
to luminal B breast cancer [134]. PyMT-MMTV mice develop lung metastases within 3 months, making 
them the most common genetically engineered mouse model in breast cancer metastasis research.  
Lungs of injected mice were dissected at different time points and processed into tissue sections. The 
potential interaction between DCs and metastases was investigated by identification, quantification and 
characterization of DC contents in metastases and DCs surrounding metastases through 
immunofluorescence of tissue sections. We cannot draw a definite conclusion about whether lung 
dendritic cells are involved in immune responses against infiltrating metastatic cells. We conclude by 




CD11c+ Particles are Found in Lung Metastases Formed by Intravenously Injected PyMT-MMTV 
Mammary Tumor Cells 
In the experiment, we dissected mammary tumors from mice of the ROSAmT/mG;PyMT-MMTV model, 
in  whose cells express tdTomato fluorescence proteins [19]. We then isolated tdTomato+ tumor 
clusters by mechanically mincing and enzymatically digesting dissected tumors into organoids and 
trypsinizing organoids into single cells or clusters with 2-10 cells, which are both mentioned as “clusters” 
hereinafter. Then about one million clusters were injected into the tail vein of an unlabeled wildtype 
FVB mouse. Lungs were dissected and fixed from the injected mouse 2 h after tail vein injection. We 
then sectioned the lungs into slides and stained one slide with an antibody against CD11c, the classical 
marker of dendritic cells. The schema of the experiment is shown in Figure 1. 
We found CD11c+ particles colocalized to lung metastases expressing tdTomato (Figure 2A, C, D, F). 
Those CD11c+ particles were found overlapped with 158 of 179 metastases on the lung section (Figure 
2H). Each metastasis was overlapped with about 7 CD11c+ particles on average (Figure 2G), although the 
distribution of those particles was highly diverse, with examples overlapping with no or many CD11c+ 
particles found. Large metastases with many particles are shown in Figure 2A and Figure 2C; a large 
metastasis without any particle is shown in Figure 2E; three small metastases with no, one and seven 
particles respectively are shown in Figure 2D. Furthermore, some metastases were wholly or partially 
stained with the anti-CD11c antibody besides colocalized with CD11c+ particles. Such cell- or cluster-
level staining usually showed lower fluorescence intensity. (Figure 2F). According to Figure 2E, sizes of 
CD11c+ particles were highly various, ranging from 0.5 to 6 μm in diameter, with the average 1.33 μm. 
Figure 2F shows that about 36% of those particles are smaller than 1 μm in diameter and thus fulfill the 
size criteria of ectosomes [98], and the rest 64% are larger than 1 μm. 
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In order to distinguish whether the overlapping particles were inside metastatic cells or on their cell 
surfaces, another slide was stained without permeabilization and use of Triton X-100. Because tissue 
fixing with paraformaldehyde (PFA) in PBS solution cannot permeabilize cellular membranes thoroughly, 
permeabilization with detergents like Triton X-100 is required for staining intracellular molecules [135]. 
In other words, omission of permeabilization and removal of Triton X-100 in each buffer used in tissue 
immunofluorescence staining can lead to labeling of membranous proteins with a greatly reduced 
possibility of staining inside the cells [136], [137]. We refer to staining with permeabilization as 
"complete staining" and staining without Triton X-100 as “membranous staining”. 
Figure 2H and 2G show that membranous staining successfully removed CD11c+ particles seen to 
overlap with metastases on the complete staining slide: only 28 of 173 metastases are found to be 
overlapped with CD11c+ particles. At the same time, the staining of CD11c on cellular membranes was 
maintained (Figure 2C). Accordingly, our data suggest that these CD11c+ particles are mostly located 
inside metastatic cells. 
Co-staining with CD11c and CD24 Antibodies Shows that the CD11c+ Particles May Not Come from 
Dendritic Cells 
Although CD11c is widely used as a classical marker of DCs, this molecule is also found in other cell types. 
We tried to further characterize the CD11c+ particles in the metastases to see whether they derived 
from DCs. Since in mouse lungs, macrophages express CD11c at a similar level to dendritic cells [95], we 
stained CD24, a marker to distinguish dendritic cells and macrophages, along with CD11c in another 
section to verify whether the CD11c+ particles found were derived from dendritic cells. We assumed 
that particles derived from CD11c+ CD24+ dendritic cells could be stained with both antibodies.  
Figure 3A shows how CD11c+ and CD11c+ CD24+ are identified: CD11c+ particles are particles with 
higher fluorescence intensity compared to its surroundings; CD11c+ CD24+ particles are determined by 
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checking whether a CD24+ particle, with higher fluorescence intensity compared to its surroundings, 
colocalize with a detected CD11c+ particle. Although cell- or metastasis-level staining of CD11c and 
CD24 was found in about 36% and 27% of metastases we analyzed respectively, CD11c+ and CD24+ 
particles with higher fluorescence intensity are still identifiable (examples shown in Figures 3A and E). If 
a CD24+ particle overlap partially with a CD11c+ particle, they are not considered as a CD11c+ CD24+ 
particle, as explained in Figure 3E.  
We found that most CD11c+ particles were not co-stained with CD24: among 437 metastases analyzed 
on this section, the mean of CD11c+ particles (including CD11c+ CD24+ particles) in a metastasis was 1.2, 
while that of CD11c+ CD24+ particles was 0.06 only; about 41% were detected with CD11c+ CD24- 
particles , while only 1.83% were with CD11c+ CD24+ particles (Figure 3C). An example of metastases 
with many CD11c+ particles but no co-stained particles is shown in Figure 3E. Those results show that 
most of those CD11c+ particles do not co-stain with CD24. 
Particle Numbers in a Metastasis is Found to Be Correlated With its Cell Number 
We analyzed whether the number of particles in a metastasis was relevant to its size, represented by the 
cell number in a metastasis. We classified metastases co-stained with antibodies against CD11c and 
CD24 into three groups: 136 individual cells, 259 small clusters with 2-10 cells, and 43 large clusters with 
more than 10 cells. While 80% of individual cells were found without any particle, the percentage was 
reduced to 54.83% for small clusters and lower than 20% for large clusters; in contrast, about 60% large 
clusters were colocalized with more than one particle, while that percentage was only about 6% for 
individual cells (Figure 3F). It shows that the distribution of particles among metastases was correlated 
with the size of a metastasis. 
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Characterization of CD11c+ Particles Through Staining of Arf6 
We tried to determine the type of CD11c+ particles. Since the particles were too large to be exosomes, 
whose sizes should be 50-150 nm in diameter, and some of them fell under the size range of ectosomes, 
we stained another slide with antibodies against CD11c and Arf6. Multiple membrane proteins have 
been labeled as markers of ectosomes [138]. We chose Arf6 among those markers in the experiment 
because Arf6 is specifically involved in release of ectosomes [101]. While other ectosomemarkers, such 
as EGFR and integrins, may also be expressed in other vesicles released by cells such as apoptotic bodies.   
The procedures of determination of CD11c+ Arf6+ particles are similar to those of determination of 
CD11c+ CD24+ particles: they are determined by checking whether an Arf6+ particle, with higher 
fluorescence intensity compared to its surroundings, colocalize with a detected CD11c+ particle. Figure 
4A shows a metastasis expressing CD11c+ Arf6+ particles. 
However, many fewer metastases were found to be overlapped with CD11c+ particles on this slide, not 
mentioning CD11c+ Arf6+ particles. Among 88 metastases analyzed, only 12.6% were found with 
particles with CD11c staining and 3.4% were found with CD11c+ Arf6+ particles (Figure 4D).  In other 
words, among 23 CD11c+ particles found on the slide, 4 were co-stained with two antibodies (Figure 4E).  
Furthermore, more than half of the metastases were found to be stained with the Arf6 antibody 
thoroughly: while for metastases without CD11c+ particles, half were stained with Arf6 (as shown in 
Figure 4B), and half were not stained (as shown in Figure 4C), all metastases with CD11c+ particles were 
stained like Figure 4A (Figure 4F).  
Quantification of CD11c+ and CD11c+ CD24+ Cells Surrounding Metastases 
We then investigated dendritic cells surrounding metastases by assessing membranous staining of 
antibodies against CD11c and CD24. We first counted CD11c+ cells located within a circle with a radius 
of 100 μm with a metastasis as its center, and then checked whether their membranes were also stained 
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with CD24 at least partially. An example is shown in Figure 5A.  Some cells were seen to overlap with 
blots of CD24 staining, but shapes of those cells and blots did not completely overlap. In such cases, 
those blots were not considered as results of expression of CD24 on those cells, and those cells were not 
counted as CD11c+ CD24+ cells. 
Figure 5C shows that there were 5.88 cells expressing CD11c surrounding a metastasis on average, and 
among them 4 also expressing CD24 and were thus considered as dendritic cells. It shows that staining 
of CD24 besides CD11c can filter other CD11c-expressing cells from dendritic cells. 
As shown in Figure 5B, metastases were various in size: among 138 metastases analyzed, 10.14% were 
individual cells, 75.36% were small clusters with 2-10 cells, and 14.50% were large clusters with more 
than 10 cells. We attempted to investigate the potential relationships between the size of a metastasis 
and numbers of cells expressing CD11c (including co-stained cells) or expressing both CD11c and CD24 
surrounding it. According to Figure 5D (for CD11c+ cells) or Figure 5E (for co-stained cells), we did not 
find a correlation between metastasis size and numbers of surrounding stained cells.  
Metastases were not distributed homogeneously, with some gathering in some regions. Therefore, we 
also investigated whether metastasis density led to strengthened gathering of antigen-presenting cells 
surrounding metastases, especially if two metastases were located within 100 μm. We classified 
metastases into those distributed in “low density”, whose distances from other metastases were at least 
100 μm, as shown in Figure 5F, and those distributed in “high density”, which were nearer than 100 μm 
away from at least one another metastasis, as shown in Figure 5G. The comparison of CD11c+ cells or 
CD11c+ CD24+ cells surrounding low-density and high-density metastases does not show correlation 
between accumulation of metastases and of stained cells (Figure 5H). 
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Membranous Staining Removes Cell- or Metastasis-Level Staining of CD11c but Not Staining of CD24 
We investigated that whether membranous staining without Triton-X-100-mediated permeabilization 
influenced cell- or metastasis-level staining of metastases by two antibodies, since metastases stained 
with the CD11c antibody, the CD24 one or both were found in both sections, as shown in Figures 3A, 3E 
and 5A. According to Figure 3D, among 448 metastases analyzed on the permeabilized slide, about 36% 
were thoroughly or partially stained with the CD11c antibody (examples can be seen in Figures 3A and 
3E), while only 8% of 138 metastases on the slide stained without Triton X-100 were stained that 
antibody. On the contrary, 119 metastases stained completely, and 78 metastases stained 
membranously were found to be stained with the CD24 antibody. It indicates that membranous staining 
can remove cell- or metastasis-level staining of the CD11c antibody but not that of the CD24 antibody. 
Dynamics of Dendritic Cells Between 6 h and 7 d After Tail Vein Injection 
In order to understand how dendritic cells are involved in early time of colonization of metastasis, we 
injected 250,000 tdTomato+ PyMT-MMTV clusters into each of four wildtype FVB mice, and dissected 
their lungs 6 h, 24 h, 48 h, and 7 d after tail vein injection respectively. Then those lungs were sectioned 
into slides for further use. First, we determined the densities of metastases of those lungs. Examples of 
those sections are shown in Figure 6A. Based on two serial sections, metastasis density kept decreasing 
during the duration from 0.8 metastasis per cm2 6 h after injection to fewer than 0.1 metastasis per cm2 
7 d after injection (Fig. 6B). The 7-d sample was not used later because of too low metastasis density. 
Then 2 sections were selected from each time point and were stained with antibodies against CD11c and 
CD24 membranously. Then the numbers of CD11c+ and CD11c+ CD24+ cells were counted through the 
method mentioned in Figure 5A. As shown in Figure 5C, 43 metastases, with 25 individual cells and 18 
clusters were analyzed on 6 h slides; 30 metastases, with 9 individual cells and 21 clusters were analyzed 
on 24 h slides; 3 single cells were analyzed on 48 slides. Figure 5D shows that there is no significant 
change in numbers of CD11c+ cells or CD11c+ CD24+ cells surrounding metastases between 24 h and 48 
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h: there were 3.34 cells expressing CD11c surrounding a metastasis on average, in which 2.41 cells also 
expressed CD24; as for 48-h slides, the average CD11c+ cell number was 3.1 while that of CD11c+ CD24+ 
cells was 2.5. The 48-h metastases were not considered because they were too few. A 24-h example is 








Figure 1 Schematic of Lung Metastasis Assay 
Clusters that are isolated from tumors of PyMT-MMTV mice expressing tdTomato markers are injected into 
wildtype mice, whose lungs are dissected after a designated time. The dissected lungs are then fixed and 
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Figure 2 CD11c+ Particles are Found in Lung Metastases 
(A-B) Comparison between metastases stained through complete staining (A) or membranous staining 
(B). 
(C-E) Different CD11c+ staining situations shown in metastases: 
(C) A large metastasis with many CD11c+ particles. 
(D) Three small metastases with multiple particles (pointed by the yellow arrow), one particle (green 
arrow) or no particle (white arrow) respectively. 
(E) A large metastasis with no CD11c+ particle. 
(F) A large metastasis with both CD11c+ particles and a metastasis-level CD11c+ staining. 
(G) Numbers of particles found in tdTomato+ metastases on sections stained through different staining 
processes. (Data are presented as mean ± SD, Kolmogorov-Smirnov test, p<0.0001). 
(H) Proportions of metastases stained with or without tdTomato+ on sections stained through different 
staining processes. (Fisher’s exact test, two-sided, p<0.0001). 
(I) Sizes of CD11c+ particles. 
























Figure 3 CD11c and CD24 Double Staining to Determine the Source of CD11c+ Particles 
(A) Determination of CD11c+ and CD11c+ CD24+ particles: CD11c+ particles are firstly found according 
to the AF647 channel (CD11c) image, a CD11c+ particle should be a particle with much higher AF647 
intensity than its surroundings, even if the its surroundings are also stained, then the AF488 (CD24) 
channel image is checked to see whether the location of the CD11c+ particle is also stained with CD24 
with much higher intensity. In this case, the particle pointed by the yellow arrow is considered CD11c+ 
CD24+, while ones pointed by white arrows are not, because they are not stained with CD24, or the 
staining is not brighter than its surrounding. 
(B) Numbers of CD11c+ and CD11c+ CD24+ particles in a metastasis (CD11c+ CD24+ particles are 
included in CD11c+ particles. Data are presented as mean ± SD, Kolmogorov-Smirnov test, p<0.0001). 
(C) Proportions of metastases according to types of particles inside. 
(D) Proportions of Metastases on sections through complete or membranous staining according to cell- 
or metastasis-level staining of CD11c or CD24 antibodies.  
(E) An example of a metastasis which is stained with both CD11c and CD24 in a metastasis level and is 
found with quite a few CD11c+ particles but no CD11c+CD24+ particles (A region containing three 
CD11c+ particles is enlarged, with the thresholds of CD11c and CD24 modified to highlight particles. 
CD11c+ particles pointed by white arrows do not overlap with CD24 particles pointed by green arrows. 
One CD11c+ particle is circled with yellow dots to show that it does not overlap with the CD24 particle 
circles with red dots. 
(F) Percentages of metastases according to CD11c+ particles inside, divided into three groups according 
to cell numbers of metastases: individual cell, small clusters with 2-10 cells, and larger clusters with 









Figure 4 Investigation of the Type of CD11c+ Particles with 










Figure 4 Investigation of the Type of CD11c+ Particles with Arf6, an Ectosome Marker 
(A) Determination of CD11c+ and CD11c+ Arf6+ particles: similar to determination of CD11c+ and 
CD11c+ CD24+ particles. One CD11c+ particle is pointed by a white arrow, and two CD11c+ particles are 
pointed by yellow arrows. 
(B) An example of metastases without CD11c+ particles and are stained with Arf6. 
(C) An example of metastases without CD11c+ particles and are not stained with Arf6. 
(D) Proportions of metastases according to types of particles inside. 
(E) Numbers of CD11c+ and CD11c+ Arf6+ particles in a metastasis (CD11c+ Arf6+ particles are included 
in CD11c+ particles). 































Figure 5 Quantification of CD11c+ CD24+ Dendritic Cells Surrounding Metastases 
(A) Determination of CD11c+ and CD11c+ CD24+ cells: CD11c+ cells are marked with yellow squares and 
CD11c+ CD24+ cells are marked with red squares. CD11c+ CD24+ cells are cells that are within 100 μm 
away from a metastasis, with nuclei stained with DAPI, membranes stained with CD11c but not 
tdTomato, and CD24 staining should be at least partially colocalized with CD11c+ membranes. Therefore, 
cells pointed by white arrows are not consider CD24+ although there are CD24 staining over cells, while 
cells pointed by yellow arrows are considered CD11c+ CD24+ because they have membranes stained 
with CD11c and at least partially stained with CD24. 
(B) Comparison Between CD11c+ and CD11c+ CD24+ Cells Surrounding a Metastasis (CD11c+ CD24+ cells 
are included in CD11c+ cells. Data are presented as mean ± SD).  
(C) Proportions of metastases according to numbers of cells inside. 
(D-E) Correlation between numbers of cells in a metastasis and CD11c+ cells (D) or CD11c+ CD24+ cells 
surrounding it. 
(F-G) Examples of metastases distributed in low density (F), where distances between metastases are 
larger than 100 μm, or in high density (G) where distances between multiple metastases are smaller 
than 100 μm. 
(H) Comparison of CD11c+ or CD11c+ CD24+ cells surrounding metastases distributed in low and high 
density. (Data are presented as mean ± SD, Welch’s t test, p = 0.9290 for CD11c+ cells, p = 0.8028 for 






















Figure 6 Dynamics of Metastases and CD11c+ or CD11c+ CD24+ Cells between 6 h and 7 days 
(A) Examples of lung sections 6 h, 24 h, 48 h, and 7 d after tail vein injection. 
(B) Densities of metastases on sections from lungs dissected 6 h, 24 h, 48 h, and 7 d after tail vein 
injection. 
(C) Numbers of individual cells and clusters on sections from lungs dissected at different time points 
stained with CD11c and CD24. 
(D) Numbers of CD11c+ and CD24+ cells surrounding a metastasis in lungs dissected 6 h, 24h, and 7 d 
after tail vein injection (Data are presented as mean ± SD, Welch’s t test, p = 0.7385 for CD11c+ cells, p = 
0.8964 for CD11c+ CD24+ cells). 
(E) An example from a 6 h slide (a CD11c+ cell is surrounded by a green square, and two CD24+ CD11c+ 
cells are surrounded by red squares). 
(F) An example from a 24 h slide (two CD11c+ cells are highlighted by green arrows, and two CD24+ 





In these experiments, we investigated the involvement of DCs in early stages of breast cancer metastasis. 
We found particles stained with CD11c colocalized with tdTomato-labeled metastases in lungs. Those 
particles appear to be located inside metastatic cells rather than on cellular membranes. We 
characterized those particles by double staining of CD11c and CD24, in order to determine the sources 
of those particles, or by staining of CD11c and Arf6, an ectosome marker, in order to determine the 
types of those particles. Then, the involvement of DCs in immune response against metastases was 
investigated by counting CD11c+CD24+ cells surrounding tdTomato-expressing clusters. The comparison 
between numbers of CD11c+ and CD11c+CD24+ cells surrounding metastases showed necessity of using 
another marker besides CD11c to prevent influence of other CD11c+ cells in research relevant to DCs. 
We tried to correlate the number of DCs surrounding a metastasis with the size or density of metastases 
in the region. Finally, we tried to see the dynamics of DCs surrounding colonizing metastases by 
quantifying CD11c+ and CD11c+CD24+ cells around metastases in lungs dissected 6h, 24h, 48h, or 7 days 
after tail vein injection.  
CD11c+ Particles 
In the experiment, particles stained by CD11c were found inside metastases in lungs after tail vein 
injection. Although CD11c is a classical marker for dendritic cells and CD11c+ extracellular vesicles 
derived from CD8α+ DCs have been found in mouse lungs [139], whether the CD11c+ found in this 
experiment requires verification, because in mouse lungs, tissue-resident macrophages can also express 
CD11c and release ectosomes during inflammation or cancer besides DCs [140], [141]. Furthermore, 
macrophages have been found to transfer cytoplasmic content to melanoma cells through direct contact 
between cellular membranes [125]. Therefore, we stained lung sections with the antibody against CD24, 
a marker to distinguish DCs and macrophages, besides the CD11c antibody to investigate the sources of 
CD11c+ particles.  
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Available data suggest that most CD11c+ particles did not co-stain with the CD24 antibody, so they may 
not have been released by dendritic cells. For example, CD24+ EVs can be secreted by normal tubule 
cells and podocytes in the kidneys, B-cells, ovarian carcinoma cells and T-cell lymphoma cells [142]-[145]. 
Therefore, this molecule can be considered releasable via EVs. The possibility that the CD11c+ particles 
are derived from DCs is thus reduced. In future, macrophage markers such as F4/80 may be co-stained 
with CD11c to investigate whether those particles are released by CD11c+ macrophages rather than DCs. 
We also tried to characterize the types of CD11c+ particles besides their sources. Since their sizes ranged 
between 0.5 μm and 6 μm in diameter, those particles were not considered to be exosomes, which 
should be smaller than 0.15 μm, but a number of them meet the size criteria of ectosomes (0.1 – 1 μm) 
or apoptotic bodies (0.05 – 5 μm). In the experiment, we tried to verify whether at least some of the 
CD11c+ particles were ectosomes by staining them with the antibody against Arf6 besides CD11c.  
We cannot draw a definitive conclusion about whether CD11c+ particles are ectosomes through staining 
of Arf6. The particles found on the section stained with anti-CD11c and anti-Arf6 antibodies were quite 
few. Many metastases were found expressing Arf6 at a high level, especially those found with CD11c+ 
particles, making determination of Arf6+ particles more difficult. Arf6 is found to be significantly 
correlated with metastases of multiple cancers including breast cancer [146], so it may not be a good 
marker for ectosomes in this research because of high background caused by cellular expression of this 
protein. Considering that many markers to label ectosomes are either cytosolic proteins which can also 
be expressed in recipient cells or are membranous proteins which can also be found in other EVs such as 
apoptotic bodies, the issue of high background may be inevitable in ectosome research that relies on 
tissue immunofluorescence staining. Therefore, a good strategy is to digest dissected lungs from 
injected mice into single cells, isolate tdTomato+ metastatic cells through FACS, digest isolated 
malignant cells and isolate CD11c+ particles through FACS again. Then those isolated particles can be 
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characterized by staining of relevant markers and flow cytometry. RNA-seq can also be performed to 
characterize potential microRNA contents inside those particles. 
Since many CD11c+ particles also meet size criteria for apoptotic bodies, markers for apoptotic bodies 
can be stained to characterize the CD11c+ particles. The TUNEL assay to stain terminals of DNA 
fragments has been reported to detect apoptotic bodies on a tissue section [147]. Therefore, in the 
future, this assay may also be used to further investigate such particles. 
Furthermore, detergents such as Triton X-100 can permeabilize cellular membranes so that antibodies 
can infiltrate into cells to stain intracellular proteins [135], but they may also damage cellular 
membranes, leading to formation of artifacts which were not seen on slides stained without 
permeabilization. CD11c+ particles may be such artifacts caused by permeabilization. In order to clarify 
whether the CD11c+ particles are artifacts resulting from the Triton X-100 treatment, sections of 
primary tumors stained with the anti-CD11c+ antibody or a control antibody with or without 
permeabilization can be compared. If CD11c+ particles can be found in complete staining without Triton-
X but not in membranous staining without Triton-X, CD11c+ particles are more likely to be artifacts. 
CD11c+ Staining on Metastases and Permeabilization in Immunofluorescence Staining 
There is no report that cancer cells express CD11c. However, many metastases in the research were 
found to be stained by the anti-CD11c antibody, either in the form of CD11c+ particles or dispersed 
staining. However, staining without permeabilization via Triton X-100 was found to reduce such staining 
by CD11c+, while the staining of CD24 was not reduced. It seems that the CD11c staining was inside 
metastatic cells while the CD24 staining was on cellular membranes. It is noteworthy that in contrast to 
CD11c, CD24 is found to be expressed in multiple malignancies including breast cancer [148].  
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The use of Triton X-100 for permeabilization can lead to loss of cell surface proteins [137]. Since both 
CD11c and CD24 are surface markers expressed on cellular membranes, membranous staining without 
Triton X-100 was applied in later research relevant to CD11c+ and CD11c+ CD24+ cells.  
It is possible that the CD11c+ staining in metastases are artifacts caused by Triton-X permeabilization, 
similar to CD11c+ particles. Comparison of primary tumor sections stained with the CD11c antibody and 
a control antibody can help verify whether the CD11c+ staining in metastases is a true signal. 
Co-staining of CD11c and CD24 Rather Than CD11c for Labeling of Dendritic Cells 
The double staining of lung sections with CD11c and CD24 demonstrates that not all CD11c+ cells 
express CD24. It supports previous research done through flow cytometry relevant to the usage of 
CD11c as a general marker of DCs in the form of immunostaining: not only DCs express CD11c in mouse 
lungs [95]. Therefore, results from previous research done with CD11c as the only label for DCs should 
be taken with caution. In the future, macrophage markers such as F4/80 can be labeled along with 
CD11c and CD24 to see whether the CD11c-expressing cells in lungs are composed of DCs and 
macrophages. Considering the finding that mouse DCs downregulate expression of CD11c upon 
activation [149], the use of additional markers with CD11c to stain DC markers should be performed. 
CD11c+ and CD11c+ CD24+ Cells Surrounding Metastases 
According to results of membranous staining of lungs dissected 2 h after tail vein injection, the number 
of CD11c+ or CD11c+ CD24+ cells surrounding metastases was not found to correlate with metastasis 
size or density. Therefore, whether CD11c+ or CD11c+ CD24+ cells are recruited to metastases requires 
verification. Densities of stained cells surrounding metastases, not surrounding metastases and in 
normal lungs may be compared to see whether dendritic cells, lung-resident or just arriving from 
circulation, accumulate to metastases and lungs with metastases in general. Since DCs can be divided 
into multiple subtypes, certain subtypes such as cDC1s are found to be more relevant to immunity 
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against cancer [48], and cancer cells can induce phenotypical changes of DCs [85], research focusing on 
roles of certain subtypes can be implemented. Lung DCs can be divided into two subtypes: CD103+ 
CD11b- and CD103- CD11b+, and during inflammation, monocytes can be differentiated to DCs, 
expressing CD11b and Ly6C [150]. The number of fluorescence channels on an imaging device limits the 
number of immunofluorescent markers that can be assessed at one time. 
Dynamics of CD11c+ or CD11c+ CD24+ Cells Surrounding Metastases 
The current results from slides of lungs dissected 6-h and 24-h do not show change in numbers of 
CD11c+ or CD11c+ CD24+ cells surrounding metastases. Besides the aforementioned issues of DC 
recruitment by metastases and involvement of different DC subtypes, the time points used in the 
research may be too late for such research concentrated on early colonization of metastases. Because of 
difference in numbers of cancer clusters injected into the 2-h mouse and other mice (one million versus 
250 thousand), numbers of stained cells surrounding metastases cannot be directly compared between 
data from the 2-h lungs and lungs dissected at other time points. However, comparison among slides of 
lungs dissected 6 h, 24 h, 48 h, and 7 d after tail vein injection has shown a decrease of metastasis 
density. One of possible explanations is that the immune system, especially cytotoxic cells recruited by 
dendritic cells, may have engaged in immune responses against metastases at those time points. 
Therefore, in the future, lungs can be dissected sooner after cluster injection, at time points such as 30 
min, 1 h, 2 h, 4 h, and 6 h, so that earlier stages of infiltration of metastases into lungs can be analyzed. 
Utilization of Tail Vein Injection in a Metastasis Assay for Immune Research 
Animal models of metastasis created by tail vein injection of malignant cells have been applied in 
multiple experiments and many theories of metastasis are established based on results gathered from 
such research. However, such assay cannot model the influence of primary tumors onto metastasis, 
including concomitant immunity against cancer of the whole body and influence of secretions of tumors 
onto metastatic organs before colonization [58][116]. Therefore, orthotopic transplant of tdTomato+ 
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tumors can be done besides the assay with tail vein injection. The phenotypes of DCs at the very 
beginning of colonization can be compared between the two assays to see whether existence of a 
primary tumor has influence on DCs in a metastatic organ. 
Limitations 
We admit that the sample sizes of experiments involved in the thesis are small. Only 19 slides were 
analyzed in the research, with 5 sections from lungs of the mouse dissected 2 h after tail vein injection, 4 
sections from the 6-h, 24-h, and 48-h mice respectively, and 2 sections from the 7-d mouse. Sections 
from the same mouse also showed great diversity in size and metastasis number and size. Furthermore, 
three slides involving CD11c+ particles showed great variety in percentages of metastases with particles 
and numbers of overlapping particles. Therefore, more mice should be dissected for each condition and 
more sections for each mouse should be analyzed so that the conclusions drawn from the research can 
be sufficiently supported. 
Furthermore, the problem of non-specific staining occurred to immunofluorescence staining in the 
experiment, especially in the case of the anti-CD24 antibody, as shown in Figure 5A. Although staining 
was later improved by reducing the amount to antibodies used and washing slides with one more turn, 
as shown in Figures 6E and 6F, such changes in immunofluorescence procedures inevitably led to 





Mouse Lines and Breeding 
All procedures performed relevant to mice were in accordance with protocols approved by the Johns 
Hopkins Medical Institute Animal Care and Use Committee (ACUC). All mice were female and were 
backcrossed and maintained on the FVB/n background.  In the experiment, 6 wild type FVB mice, 1 
MMTV::PyMT; (R26)pCA::mT/mG mouse and 1 MMTV::PyMT; (R26)pCA::mT/mG; K14::actin-GFP were 
used. The MMTV::PyMT; (R26)pCA::mT/mG mouse is a crossbreed of mouse lines of MMTV-PyMT [134], 
R26::Cre-ER [151], and mT/mG [152].  MMTV::PyMT; (R26)pCA::mT/mG; K14::actin-GFP is a crossbreed 
of mouse lines of the former three and K14-GFP-actin [153]. MMTV-PyMT34 and mT/mG mice were 
obtained from the Jackson Laboratories. The R26::Cre-ER mouse line was a gift from J. Nathans (Johns 
Hopkins University). K14-actin-GFP mice were a gift from Elaine Fuchs (Rockefeller University, New York, 
NY). 
Isolation of Primary Mammary Gland Organoids 
The tumor clusters used in the experiment were derived from trypsinization of primary tumor organoids, 
which were isolated from mouse primary mammary tumors according to well-established protocols of 
the lab [154].  Tumors were dissected from 10-12-week-old MMTV-PyMT mice carrying a ROSAmT/mG 
reporter or both the ROSAmT/mG reporter and a K14-GFP reporter. Then, tumors were mechanically 
minced with a scalpel and enzymatically digested in a shaking incubator (Thermo Scientific MaxQ 4450) 
at 110-150 rpm for 1 h at 37°C in collagenase solution, which was prepared by adding 2mg/mL 
collagenase (C2139; Sigma-Aldrich), 2 mg/mL trypsin (27250–018; Gibco Life Technologies), 5% (vol/vol) 
FBS (F0926; Sigma-Aldrich), 5 μg/mL insulin (I9278; Sigma-Aldrich), and 50 μg/mL gentamicin (15750; 
Gibco Life Technologies) to DMEM/F12 (10565–018; Gibco Life Technologies). After removal of fat and 
debris through centrifugation at 1500 rpm for 10 min, the suspension was treated with 2 U/μL DNase 
solution in PBS (without Ca2+ or Mg2+, 10010-023; Life Technologies) for dissociation of small clusters 
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into single cells. Large chunks of tissue were removed via natural precipitation. Organoids were isolated 
from single cells by 4 cycles of differential centrifugation: in each cycle, suspension was centrifuged at 
1500 rpm for 3 s.  
Tail Vein Injection  
After washing with PBS, organoids were trypsinized into small cell clusters by incubating with TrypLE 
(12604013; Thermo Fisher) for 10 min at 37°C. Remaining organoids were filtered by pipetting 
suspension into  5 mL round bottom tubes (352235; Falcon) through their cell-strainer caps. The 
remaining clusters were counted and resuspended at a concentration of 106 or 4×106 cells/mL. They 
were transferred to 1.5 mL or 2 mL sterile Eppendorf tubes for use in tail vein injection. 
Tumor clusters collected were injected into wildtype FVB mice intravenously. After putting a mouse into 
a restrainer, its tail was dilated by a heat lamp for 5 min. Then, for each mouse, 250 μL tumor cluster 
suspension was injected into its tail vein with a U-100 insulin syringe (329461; Becton Dickinson).  
Collection and Fixation of Mouse Lungs 
Lungs of injected mice were collected 2 h, 6 h, 24 h, 48 h, or a week after tail vein injection. After 
exposing the heart and the lungs of mice by cutting its rib cage, we perfused the mouse at least 10 mL 1% 
PFA (P6148; Sigma-Aldrich) solution in PBS through the right ventricle of the heart. Then at least 10mL 
PBS was injected at the same site to clear PFA solution. Then lungs were dissected with the heart, put in 
1% PFA solution for fixation and incubated at 4°C overnight. After that, lungs were transferred to 25% 
sucrose (S7903; Sigma) solution in PBS and incubated at 4°C overnight. They were then embedded in 
Tissue-Tek OCT compound (4583; Sakura). The tissue samples embedded in OCT were sectioned into 




In the experiment, two types of immunofluorescence techniques were used, to stain membranous or 
both intracellular and membranous proteins. In both techniques, tissue sections were covered by DPBS 
(with Ca2+ and Mg2+, D8662; Sigma) for 1 h at room temperature to remove OCT. Then while in 
membranous staining sections were directly blocked with block buffer for 2 h at room temperature, in 
complete staining the section was permeabilized with 0.5% Triton X-100 (X100; Sigma) solution in PBS 
before blocking. Then sections were incubated with conjugated antibodies and primary antibodies 
diluted in dilution buffer overnight at 4°C. After being rinsed with PBS for 10 min 2-3 times, sections 
were incubated with DAPI and secondary antibodies diluted in dilution buffer for 4 h at room 
temperature. Then sections were rinsed with PBS for 10 min 3-5 times. Sections were then mounted and 
sealed with coverslips. The formulas for block and antibody dilution buffers are shown in Table 1. 
Primary and conjugated antibodies used in the experiment were CD11c (dilution ratio 1:100, N418, 
conjugated with AF647, 117314; BioLegend), CD24 (dilution ratio 1:100-1:200, ab214231; Abcam), and 
ARF6 (dilution ratio 1:100, PA1-093; Invitrogen). Secondary antibodies were diluted with the ratio 1:200. 
DAPI was diluted with the ratio 1:1000. 
Table 1 Composition of block and antibody dilution buffers in membranous and complete staining 
 Block Buffer Antibody Dilution Buffer 
Membranous Staining 10% FBS, 1% BSA solution 
(30% in DPBS, A9576; Sigma-
Aldrich) in PBS 
1% FBS, 1% BSA solution in PBS 
Complete Staining 10% FBS, 1% BSA solution, and 
0.2% Triton X-100 in PBS 
1% FBS, 1% BSA solution, and 0.2% Triton 




Slide Scanning and Image and Statistical Analysis 
Stained and sealed slides were scanned with a Zeiss Axio Scan.Z1 and an AxioCam MRM camera (Zeiss). 
Images were processed with Zeiss ZEN 3.1. Statistical analysis was performed using GraphPad Prism 8. 
Statistical tests used for each experiment and other parameters associated with the representation of 
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important member of the innate immune system, control breast cancer metastasis, led by Dr. Isaac 
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both DIC and confocal microscopes, and their time-lapse recording functions. I learned 
immunocytochemistry, immunohistochemistry and flow cytometry. I learned to use a cryostat. I 
learned to use a high content imager and a slice scanner. I learned to use both CellEvent Caspase-3/7 
reporter and TUNEL assay to observe apoptosis. I also did ELISA assay and plenty of Western blot. I 
also learned to do ELISA. I also learned to do tail vein injection. 
Observation of Invasion Modes of Liver Cancer                                                                            Jan–Jul 2017 
The Hong Kong Polytechnic University | PI: Dr. Youhua Tan 
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This was my capstone project in the final year of the undergraduate university. The aim of the project 
was originally to research on the roles of cancer stem cells (CSCs) and non-cancer stem cells during 
tumor invasion. The hepatocellular carcinoma cell line Huh-7 were used as the model.  
I developed the 3D collagen gel tumor invasion model independently in the lab according to 
instructions of certain papers only. I learned to form spheroids from cell suspension via drop-hanging, 
which were transferred to collagen gel and were observed daily for at most 7 days. Modes of 
morphological changes happened to those spheroids, including invasion modes, were collected. 
Finally, I learned to transfect cancer cells with Lipo3000, and trying to tell whether CSCs or non-CSCs 
take the lead during tumor invasion by observing chimera spheroids formed with labeled non-CSCs 
and unlabeled CSCs through a fluorescence microscope. 
Physical Properties of Cancer Cells on Substrate with Different Viscoelasticity 
University of Pennsylvania | PI: Dr. Paul Janmey                    Oct–Dec 2017 
I worked to help a master student in research on physical properties of cancer cells on substrate with 
different viscoelasticity. I learned to make polyacrylamide gels with modulated viscoelasticity. My 
main work was to do cell tracing with ImageJ with cancer cells cultured on substrate with different 
viscoelasticity sent by the master student. 
Ultrasound Stimulation on MSCs for Recovery from Bone Fracture                              Jan–July 2016 
The Hong Kong Polytechnic University | Supervisor: Dr. Chunyi Wen 
I worked to help a master student under Dr. Wen in a project about ultrasound stimulation on MSCs 
for recovery from bone fracture. I learned to passage mesenchymal stem cells (MSCs) and to transfect 
quantom dots.  We established an experiment system with a water tank and an ultrasound generator. 
The aim of the research was to see whether quantom dots would be transferred to nuclei after 
stimulation by ultrasound. 
Work Experience  ______ 
Reagent Research and Design Intern                                                                                          June– Aug 2017 
the Biochemical Reagent R&D Department, Mindray Medical Co., Shenzhen, China 
➢ Worked as an online maintenance intern in China's largest medical equipment manufacturer; 
➢ Utilized experiment methods and root cause analysis to solve complaints about biochemical 
reagents and autoanalyzers from clients; 
➢ Gathered and analyzed data from imported database from complainers in Microsoft Excel to find 
out causes of complaints; 
➢ Detected limits of blank and limits of detection of several reagents in certain types of 
autoanalyzers; 
Market Analyst Intern                 Sept– Nov 2016 
TF Security, Shenzhen, China 
➢ analyzed the market of medical devices in China; 




Skills  ______  
Software: R language, MATLAB, Mathematica, ImageJ, GraphPad Prism, Chem3D, Microsoft Office 
(Word and Excel) 
 
Awards  ______  
➢ Dean’s Honours List of Faculty of Engineering for 3 consecutive years in the Hong Kong Polytechnic 
University (2014/2015, 2015/2016, 2016/2017) 
➢ Outstanding Student Award of the Department of Biomedical Engineering 2018 - The Hong Kong 
Polytechnic University 
Academic Interests  ______  
I am interested in how heterogeneous components of a tumor, including different subpopulations of 
cancer cells and non-cancer cells and extracellular matrices, interact with and influence each other, 
during tumor development, leading to invasion and metastasis. Dr. Kenneth Pienta describes cancer as 
a social dysfunction within a cell community, which is a description that I could not agree more.  
Then, I would like to participate in development of cellular immunotherapy against cancer, which is to 
use knowledge of cell-cell interaction as mentioned above to medicine. I am interested in development 
of proteins with domains of expected functions and gene modification via CRISPR-Cas9.  
Thirdly, I would like to do research on stem cell lineage determination via mechanical cues. In this field, 
I am most interested in the finding that mechanical cues only can lead to reprogramming of 
differentiated cells into stem cells. 
 
 
 
 
 
 
 
 
 
